Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
Stanford University
University of Nebraska
University of Nebraska
University of Nebraska
Atara Biotherapeutics
Alexion Pharmaceuticals, Inc.
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Mayo Clinic
University of Chicago
City of Hope Medical Center
Case Comprehensive Cancer Center
Northwestern University
Barbara Ann Karmanos Cancer Institute
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Massachusetts General Hospital
University of Washington
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
University of Rochester
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
Vanderbilt-Ingram Cancer Center
Fred Hutchinson Cancer Center
INSYS Therapeutics Inc
Vanderbilt-Ingram Cancer Center
Northside Hospital, Inc.